# Appendix A RCPath and NHSBSP breast pathology synoptic proforma template for surgically resected lesions, including dataset and commonly used optional items

This template is provided as an example proforma for use for synoptic reporting of breast screening and symptomatic breast disease-related specimens. It can be separated into separate documents for reporting benign, in situcarcinoma and invasive carcinoma-related cases and can be adapted to suit local needs and protocols (but must include the RCPath dataset, see Appendix B).

Sections in italics are regarded as optional (non-core).

## Pathology report

Patient’s identifier: .............................................................................................................

Date reported: .............................................. Report number: ...........................................

Pathologist: .................................................. Laboratory: ..................................................

## Surgical specimen(s)

Side: Right □ Left □

Specimen type:

Wide local excision□ Excision biopsy □ Localisation specimen □ Segmental excision □

Mastectomy □ Subcutaneous mastectomy □ Nipple sparing mastectomy □

Re-excision □ Further margins (including cavity shaves/bed biopsies) □

Microdochectomy/microductectomy □ Total duct excision/Hadfield procedure □

### Axillary procedure:

None □ Sentinel node biopsy □ Axillary sampling □ Axillary LN level I □

Axillary LN level II □ Axillary LN level III □

\*Other ..........................................................

Specimen weight (g) ..........................................

\*Comment/further macroscopic \*description: ............................................................

\*Specimen radiograph seen: Yes □ No □

\*Mammographic abnormality: Yes □ No □ Unsure □

\*Site of previous core biopsy seen Yes □ No □

\*Histological calcification Absent □ Benign □ Malignant □ Benign and malignant □

### Benign lesions

Columnar cell change □ Complex sclerosing lesion/radial scar □ Fibroadenoma □

Fibrocystic change □ Multiple papillomas □ Papilloma (single) □

Periductal mastitis/duct ectasia □ Sclerosing adenosis □ Solitary cyst □

Other □ Specify other.........................

**Epithelial proliferation**

Not present □ Present without atypia □

Flat epithelial atypia □ Present with atypia (ductal) □ Present with atypia (lobular) □

### Malignant lesions

**Malignant in situlesion**: Absent □ Present □

**In situcomponents**: DCIS □ LCIS □

DCIS grade: High □ Intermediate □ Low □ Not assessable □

DCIS growth pattern: Solid □ Cribriform □ Papillary □ Micropapillary □

Apocrine □ Flat □

Other □ Specify other......................

DCIS necrosis: Present □ Absent □

Inflammation: Present □ Absent □

DCIS size (mm): ...........................................

Paget’s disease: Present □ Absent □

Microinvasion: Present □ Absent □

**LCIS type:** Classical □ Pleomorphic □ Florid □

**LCIS size mm (for pleomorphic LCIS): ………………**

**Invasive carcinoma**  Present □ Absent □

### Size and extent

Tumour size (mm): ...................................

Whole tumour size (mm): ...............................

Disease extent: Localised □ Multiple invasive foci □ Not assessable □

**Invasive tumour type** Pure □ (tick 1 box below) Mixed □ (tick all components present below)

Tubular/cribriform □ Lobular □ Mucinous □ Invasive carcinoma NST □ Micropapillary □

Other □ Other type/component: .........................................................................................

**Histological grade** 1 □ 2 □ 3 □ Not assessable □

*\*Components (optional):*

*Tubule formation*  *1 □*  *2 □*  *3 □*  *Not assessable □*

*Nuclear pleomorphism*  *1 □*  *2 □*  *3 □*  *Not assessable □*

*Mitoses*  *1 □*  *2 □*  *3 □*  *Not assessable □*

**Lymphovascular invasion** Present □ Absent □ Possible □

### Lymph node stage

Sentinel/axillary nodes present: No □ Yes □

Total present: ..........

Total positive ……..

Total with ITCs:........... Size of metastasis : ………..mm

*\*Extracapsular spread: Present □ Not identified □*

For single node positive: Macrometastasis □ Micrometastasis □

Size of metastasis: mm

Other nodes present: No □ Yes □ Site: .........................

Total present: ..........

Total positive:...........

For single node positive: Macrometastasis □ Micrometastasis □

\**Status of perinodal fat: involved, not involved*

*\*Summary lymph node stage:*

*1 = Node negative □ 2 = 1–3 nodes positive □ 3 = 4 or more nodes positive □*

**Modifications for post-neoadjuvant therapy cases (in addition to standard dataset items)**

### Post-therapy lymph node stage

Axillary nodes:

Total present: ..........

Total positive: ...........

Total showing treatment response but no tumour cells:

Other nodes: Site: .........................

Total present: ..........

Total positive:...........

Total showing treatment response but no tumour cells:

Evidence of treatment response in the metastases: Present □ Absent □

**Final classification of chemotherapy response**

Breast disease response:

### Lymph node response:

### TNM stage

T stage: pTis □ pT1mi □ pT1a □ pT1b □ pT1c □ pT2 □ pT3 □ pT4a □ pT4b □

pT4c □ pT4d □ Cannot be assessed □

N stage: pN0 □ pN1mi □ pN1a □ pN1b □ pN1c □ pN2a □ pN2b □ pN3a □   
pN3c □ Cannot be assessed □

M stage: pM1 □ Cannot be assessed □

Note: Add suffix ‘y’ to TNM codes for post-neoadjuvant therapy treated cases

### Excision status

Distance from each margin (mm)

**Invasive**

Superior....... Inferior ......... Medial ....... Lateral .......

Deep ....... Superficial ...... Nipple margin....................

**In situ (DCIS, pleomorphic/florid LCIS)**

Superior ..... Inferior........ Medial ....... Lateral ....

Deep ...... Superficial ....... Nipple margin ................

### Receptor status

Oestrogen receptor status: Positive (≥1%) □ Negative (<1%) □ Low positive (1–10%) □

% positive tumour cells =………….

Average intensity of staining = Weak □ Moderate □ Strong □

*\*Allred score (0–8):………………………………………*

*\*H score (0–300):……………………………………….*

*\*On-slide positive control material: Present □ Absent □*

*\*Progesterone receptor status: Positive (≥1%) □ Negative (<1%) □*

*\*% positive tumour cells =………….*

*\*Average intensity of staining = Weak □ Moderate □ Strong □*

*\*Allred score (0–8):………………………………………*

*\*H score (0–300):…………………………………………*

*\*On-slide positive control material: Present □ Absent □*

HER2 IHC score: 0 Negative □ 1+ □ Negative □ 2+ Equivocal □ 3+ Positive □

*\*ISH ratio: ...........*

Status: Amplified □ Non-amplified □ Borderline □ Not performed □

*\*HER2 copy no: …... Chromosome 17 no: ……*

Final HER2 status: Positive □ Negative □

*\*Optional:*

*Proliferation (Ki67) index: .........*

**TNM stage:**

**SNOMED codes**

**T:**

**M:**

**Key**

\*Non-core data item.